HIT Consultant January 8, 2024
What You Should Know:
Niterra, a global leader in diverse industries, today announced its participation in a $10M convertible debt financing round for Imbed Biosciences, Inc. (Imbed), a rising star in the field of tissue engineering.
– This strategic investment marks Niterra’s commitment to supporting innovative solutions that improve patient quality of life and aligns perfectly with its transformation towards non-internal combustion engine businesses.
Revolutionizing Wound Care with Microlyte® Technology
Imbed has pioneered a revolutionary wound care technology called Microlyte®, the world’s first fully-synthetic and antimicrobial wound matrix. This FDA-cleared biocompatible polymer matrix creates a healing environment conducive to tissue growth while suppressing harmful microbes and biofilms. Clinical trials have demonstrated the matrix’s ability to jump-start healing in stagnant chronic...
Today's Sponsors
Today's Sponsor